WESTFIELD, N.J., Oct. 17, 2016 /PRNewswire/ -- Relburn-Metabolomics, Inc. announced that the Company has achieved key milestones in finalizing its medicinal chemistry program that targets chronic gout. Relburn scientists have synthesized derivatives of the Company’s prototype drug that act at low nanomolar concentrations against two key regulators of uric acid, the proximate cause of gout. The Company has also effectively altered the activity profile of its leads to reflect the latest clinical and safety experience with standard monofunctional drugs. In clinical studies comprising more than 350 patients, the Company’s prototype induced striking reductions in serum uric acid, including in all patients with elevated baseline levels.
“The high potency of our unique bifunctional inhibitors are clearly responsible for the striking control of uric acid observed in patients,” said Dr. Raymond P. Warrell, Jr., Relburn’s Chief Executive Officer. “We have now filed 4 worldwide, wholly owned patents on compositions and processes, and we expect to nominate a clinical lead for IND-enabling studies in the near future.”
These findings will be discussed by Dr. Warrell at the BIO Investor Forum in San Francisco on October 18, 2016 at 8:00 AM PT in the Elizabethan D Room, Westin St. Francis Hotel.
About Relburn-Metabolomics
Relburn is an emerging life-science company focused on improving health for patients with metabolic and inflammatory diseases. Relburn’s lead program includes transformational therapy for chronic gout, a disease that afflicts 16 million patients in the US/EU. Targeting enzymes that regulate both production and excretion of uric acid, Relburn compounds are markedly more potent than standard monofunctional drugs and have demonstrated exceptional clinical activity. Relburn believes its drugs may replace current 1st-line treatments for gout, thereby leading to meaningful improvements in patient well-being. Further information can be accessed at: www.relburn.com.
Relburn company information: info@relburn.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relburn-metabolomics-files-patents-on-bifunctional-nanomolar-inhibitors-of-gout-target-enzymes-300345484.html
SOURCE Relburn-Metabolomics, Inc.
